Angle gains on breakthrough in cancer diagnostic technology
Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix.
Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix.
The AIM listed company said it had edged further in the development of Parsortix, a non-invasive technology which captures and counts rare circulating tumour cells (CTC) from the blood of cancer patients.
Angle has designed a process for recovering the captured calls from the Parsotix cassette. The cells are then analysed by a variety of contemporary molecular techniques.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
CTC analysis, through the use of such techniques, extends the Parsortix technology's capability and opens up new diagnostic, prognostic and treatment applications for cancer patients.
Angle expects its market to grow as it is the first device designed to recover CTCs. Analysis of CTCs can be used to screen and diagnose patients.
The company said the technology monitors patients' response to treatment in a non-invasive manner without having to perform a tumour biopsy.
Angle's research partner, the Paterson Institute for Cancer Research, will be researching the potential for the Parsortix system.
Angle's Founder and Chief Executive, Andrew Newland, said: "This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy.
"We know from discussions with researchers and physicians that there is market demand for this versatility."
RD
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
8 of the best properties for sale with communal gardens
The best properties for sale with access to communal gardens – from an apartment in a listed building opposite London’s Hyde Park, to a wing of a mansion with access to 180 acres of parkland in Henley-upon-Thames
-
The five insurance policies you should have
Some insurance cover will be more important than others. We look at five insurance policies you may need to have to make sure you aren’t caught out in an emergency